Connect Biopharma Holdings CNTB
NASDAQ CNTB
$0.69 +0.01 (+0.98%)
At close: Nov 11, 2026 · 4:00 PM EST

Connect Biopharma Holdings (CNTB) Change in Receivables (2024 - 2026)

Updated

Connect Biopharma Holdings' Change in Receivables was $2.94 million in Q2 2026, compared with -$8,000 a year earlier.

Analysis

Connect Biopharma Holdings (CNTB) Change in Receivables (2024 - 2026) Analysis & Trends

For FY2025, Change in Receivables at Connect Biopharma Holdings came in at -$776,000.

  • In earlier years, Change in Receivables was $789,000 in FY2024.
  • The Q2 2026 figure marks the highest quarterly Change in Receivables since Q3 2024.
  • Per Business Quant data, CNTB's Change in Receivables in the three quarters before Q2 2026 was -$13,000 (Q1 2026), -$4,000 (Q4 2025) and $17,000 (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change Receivables (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn -188.00 Mn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn -312.00 Mn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn -
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 108.00 Mn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -52.00 Mn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn -
10 Connect Biopharma Holdings 42.82 Mn -133.85 Mn - 2.94 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 2.94 Mn
Mar 31, 2026 -13,000.00
Dec 31, 2025 -4,000.00
Sep 30, 2025 17,000.00
Jun 30, 2025 -8,000.00
Mar 31, 2025 -781,000.00
Dec 31, 2024 -4.23 Mn
Sep 30, 2024 5.02 Mn
API Access

Connect Biopharma Holdings Change in Receivables API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=change-in-receivables&ticker=CNTB&period=max&api_key=YOUR_API_KEY